Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Public ClinicalTrials.gov record NCT03500549. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study identification
- NCT ID
- NCT03500549
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- Pegcetacoplan Drug
- Soliris Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 13, 2018
- Primary completion
- Nov 13, 2019
- Completion
- Aug 12, 2020
- Last update posted
- Mar 24, 2022
2018 – 2020
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Southern California | Los Angeles | California | 90033 | — |
| Sarcoma Oncology Research Center | Santa Monica | California | 90403 | — |
| Denver Health | Denver | Colorado | 80204 | — |
| Georgetown University Hospital | Washington D.C. | District of Columbia | 20057 | — |
| Cancer Specialists of North Florida | Jacksonville | Florida | 32256 | — |
| Lakes Research | Miami Lakes | Florida | 33014 | — |
| Mid Florida Hematology and Oncology | Orange City | Florida | 32763 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Investigative Clinical Research of Indiana | Indianapolis | Indiana | 46260 | — |
| Cancer & Hematology Centers of Western Michigan | Grand Rapids | Michigan | 49503 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| New York Cancer & Blood Specialists | East Setauket | New York | 11733 | — |
| New York Cancer & Blood Specialists | The Bronx | New York | 10469 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Good Samaritan Hospital | Corvallis | Oregon | 97330 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| Baptist Cancer Center | Memphis | Tennessee | 38120 | — |
| HOPE Cancer Center of East Texas | Tyler | Texas | 75701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03500549, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 24, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03500549 live on ClinicalTrials.gov.